PI3K, particularly the p110α catalytic isoform, is frequently mutated in cancer, and highly specific inhibitors such as alpelisib are currently used in oncology and in <i>PIK3CA</i>-related overgrowth disorders. This evidence concerns the gene PIK3CD and cancer.